- The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda has an option to add 2 additional programs and is obligated to provide funding for all program’s R&D costs
- Poseida to receive $45M up front & preclinical milestones exceeding $125M, if milestones for 6 programs are achieved. The company is also eligible for ~2.7B milestones for all 6 programs and ~$3.6B if the milestones related to the 2 optional programs are also achieved
- Poseida will lead research activities up to candidate selection, after which Takeda will lead development & commercialization
Click here to read full press release/ article | Ref: PR Newswire | Image: Poseida
The post Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies first appeared on PharmaShots.